INTRODUCTION {#s1}
============

Cancer is a genetically and clinically diverse disease, with a tremendous amount of genetic heterogeneity across various malignant tumor types, invading and destroying nearby parts of the normal tissues \[[@R1]\]. The incidence and death rates of cancer are increasing in many cancer types, such as liver cancer, lung cancer and prostate cancer \[[@R2]\]. Besides, the survival rate of cancer patients tends to be poor for the lack of diagnostic methods with sensitivity and specificity in developing countries \[[@R3]\]. Latest research results predicted that biomarkers can be useful during the detection of cancers \[[@R4]\].

Extracellular matrix metalloproteinase inducer (EMMPRIN, basigin, HAb18G, also known as CD147) is a type I transmembrane glycoprotein of the immunoglobulin superfamily with two immunoglobulin-like domains \[[@R5], [@R6]\]. EMMPRIN has been shown to be involved in various physiological as well as pathophysiological processes such as proliferation, migration, inflammation reaction and tumor invasion \[[@R7], [@R8]\]. An increasing number of studies have demonstrated that EMMPRIN is associated with tumor growth, invasion and angiogenesis in many malignant cancer, such as breast carcinoma \[[@R9]\], hepatocellular carcinoma \[[@R10]\] and prostate cancer \[[@R11]\], by regulating the expression of matrix metalloproteinases (MMPs) and vascular endothelial growth factor (VEGF) \[[@R12]\]. MMPs have been shown to decrease the angiogenesis of tumor cells and the expression of extracellular matrix, thereby contributing to tumor progression \[[@R13]\]. Recently, some research data indicated that expression of EMMPRIN was obviously higher in tumor tissues than adjacent normal tissues, indicating that EMMPRIN might be useful for the prediction of prognosis in cancers.

In this study, we performed a systematically meta-analysis to investigate the relationship between EPPRIN and cancers. The aim of this study is to evaluate the clinical significance of EPPRIN and its potential value when served as a prognostic indicator.

RESULTS {#s2}
=======

Search results and study characteristics {#s2_1}
----------------------------------------

As presented in Figure [1](#F1){ref-type="fig"}, 992 potentially eligible studies from the databases were retrieved after duplicates removed. Through a carefully screening process, 938 articles were excluded. Of the remaining 54 studies, 15 studies were excluded for they did not meet the inclusion criteria. Finally, 39 cohort studies were included in our meta-analysis \[[@R13]--[@R51]\].

![Flow diagram of the study selection process](oncotarget-08-82643-g001){#F1}

The major characteristics of studies included were listed in Table [1](#T1){ref-type="table"}. Among them, 29 were conducted in China, 3 from Germany, 2 from Portugal, 2 from Norway and 3 from America, Finland and Brazil respectively. We included a total of 5739 cases with different types of tumors, including bladder carcinoma, renal carcinoma, prostate carcinoma, penis carcinoma, colorectal cancer, breast cancer, thyroid carcinoma, ovarian carcinoma, glioblastoma. The testing methods of EMMPRIN were classified as immunohistochemistry (IHC) and tissue microassay. IHC staining was carried out using the paraffin-embedded block of cancer patients' tissues compared to corresponding normal tissue, and the percentage of positive cells was calculated. The cut-off value was also list in Table [1](#T1){ref-type="table"}.

###### Characteristics of 39 pooled studies evaluating the association between EMMPRIN overexpression and cancer

  First author          Year   Country    Cancer type                                  Sample size   Mean age     Out comes   RR (95% CI)         Testing method      Cut-off value
  --------------------- ------ ---------- -------------------------------------------- ------------- ------------ ----------- ------------------- ------------------- -----------------
  Zhaodong Han1         2008   China      Bladder carcinoma                            58            57.2± 11.2   PFS         3.66 (1.04-12.79)   IHC                 3+ (\>51%)
  Zhaodong Han2         2008   China      Renal carcinoma                              52            56.8± 10.8   PFS         3.06 (0.82-11.44)   IHC                 As above
  Zhaodong Han3         2008   China      Prostate carcinoma                           101           73.5± 12.3   PFS         4.87 (1.77-13.41)   IHC                 As above
  Zhaodong Han4         2008   China      Penis carcinoma                              17            46.5± 9.2    PFS         2.38 (0.34-25.30)   IHC                 As above
  Zhaodong Han5         2008   China      testis carcinoma                             17            48.6± 12.7   PFS         1.79 (0.22-19.94)   IHC                 As above
  Albrecht Stenzinger   2011   Germany    Colorectal cancer                            285           67           OS          3.09 (1.91-5.02)    Tissue microassay   NM
  Jung-Woo Choi         2014   China      Bladder cancer                               360           69           OS          1.15 (0.50-2.67)    Tissue microassay   Scores 3
  WeiDe Zhong           2010   China      Bladder cancer                               101           68           PFS/OS      3.31 (1.07-15.72)   IHC                 1 (\>10%)
  HUI TAN               2008   China      Thyroid carcinoma                            156           46           PFS         3.31 (1.07-15.72)   IHC                 3+ (\>51%)
  Xiaoyan Xua           2013   China      Non-small cell lung cancer                   192           60           OS          6.63 (2.46-17.90)   IHC                 3+ (\>51%)
  J. Afonso             2011   Portugal   Bladder carcinoma                            77            71           PFS/OS      3.25 (1.02-10.39)   IHC                 1 (\>5%)
  Xinjie Yang           2010   China      Adenoid cystic carcinoma                     72            58           OS          2.78 (1.25-6.19)    IHC                 NM
  YauHua Yu             2015   America    squamous cell Carcinoma of the oral tongue   31            60           PFS/OS      2.82 (0.60-13.26)   IHC                 Grade 2 (\>25%)
  Pascale Fisel         2015   Germany    Clear cell renal cell Carcinoma              186           64           OS          5.50 (2.50-12.10)   IHC                 Score 3
  Daniel Buergy         2009   Germany    Colorectal cancer                            40            58           OS          2.50 (0.27-23.55)   IHC                 \>30%
  Ovarian Cancer        2007   Finland    Ovarian cancer                               282           61           PFS         1.32 (0.98-1.80)    IHC                 \>10%
  Ben Davidson          2003   Norway     Ovarian carcinoma                            41            59           OS          2.10 (0.76-5.81)    IHC                 NM
  Jian Gu               2008   China      Pediatric gliomas                            45            62           PFS         0.32 (0.11-2.09)    IHC                 \>51%
  Songlin Piao          2012   China      Salivary duct carcinoma                      35            59           PFS/OS      2.95 (1.25-6.94)    IHC                 Score 6
  Fangfang Liu          2010   China      Breast carcinoma                             110           53           PFS/OS      2.18 (0.61-7.81)    IHC                 \>30%
  Antônio Talvane       2012   Brazil     Gastrointestinal stromal tumors              64            62           OS          1.13 (0.24-5.25)    IHC                 Score 3
  Min Yang              2013   China      Glioblastoma                                 206           57           OS          2.42 (1.35-4.18)    IHC                 Score 3
  Wei Wu                2008   China      Gallbladder carcinoma                        60            52           OS          0.49 (0.21-1.72)    IHC                 \>75%
  Tiefu Chen            2010   China      Primary cutaneous Malignant melanoma         150           53           PFS/OS      7.32 (1.19-20.29)   IHC                 \>10%
  YiJun Xue             2011   China      Bladder cancer                               118           58           OS          2.33 (1.15-4.73)    IHC                 \>51%
  Ying Liu              2013   China      Basal-like breast cancer                     126           56           PFS/OS      5.41 (0.74-39.49)   IHC                 NM
  Shaojun Zhu1          2013   China      Colorectal cancer                            163           53           OS          8.88 (5.52-14.82)   IHC                 Score 3
  Shaojun Zhu2          2013   China      Colorectal cancer                            194           53           OS          3.51 (2.03-6.08)    IHC                 As above
  Shaojun Zhu3          2013   China      Colorectal cancer                            213           53           OS          1.89 (1.06-3.38)    IHC                 As above
  Zhaodong Han1         2009   China      Prostate Cancer                              39            74           OS          4.49 (0.29-69.18)   IHC                 Score 2 (\>25%)
  Zhaodong Han2         2009   China      Prostate Cancer                              34            74           OS          3.54 (0.24-51.94)   IHC                 As above
  Che Zhang             2010   China      Intrahepatic Cholangiocarcinoma              49            66           OS          0.98 (0.76-2.01)    IHC                 \>51%
  Tongwei Chu           2011   China      Pediatric Medulloblastoma                    55            59           OS          3.50 (1.60-5.10)    IHC                 Grade 2 (\>10%)
  Xiaoxia Gou           2014   China      Laryngeal                                    48            64           OS          4.87 (0.47-23.50)   IHC                 Score 3
  Xinwen Zhong          2013   China      Pulmonary Adenocarcinoma                     180           68           OS          2.01 (1.26-3.21)    IHC                 Score 3 (\>51%)
  K Boye                2012   Norway     Colorectal cancer                            277           NR           OS          3.30 (1.40-7.80)    IHC                 Score 2 (\>25%)
  Luís SilvaMonteiro    2014   Portugal   Oral Squamous Cell Carcinomas                74            62           OS          3.89 (1.11-13.71)   IHC                 Score 5
  XingZhu Ju            2008   China      Cervical Cancer                              82            52           PFS         1.23 (0.52-2.90)    IHC                 \>51%
  XinQiong Huang        2014   China      Cervical Cancer                              132           51           PFS         5.12 (2.56-12.78)   IHC                 \>25%
  LingMin Kong          2011   China      Hepatocellular carcinoma                     54            60           OS          2.13 (0.78-5.79)    Tissue microassay   Score 3
  Shu Zhao              2013   China      Ttriple-negative breast cancer               127           47           OS          2.68 (1.08-6.66)    IHC                 NM
  Li Tian1              2013   China      Astrocytic glioma                            182           65           OS          2.57 (1.41-4.83)    IHC                 Score 3
  Li Tian2              2014   China      Astrocytic glioma                            151           65           OS          4.52 (2.88-10.96)   IHC                 As above
  Li Tian3              2015   China      Astrocytic glioma                            125           65           OS          6.61 (3.62-13.21)   IHC                 As above
  Dake Chu              2013   China      Gastric cancer                               223           60           PFS/OS      1.59 (1.05-2.40)    IHC                 Score 3
  Weide Zhong           2012   China      Prostate cancer                              240           62           OS          3.08 (1.62-5.85)    Tissue microassay   NM
  Shaojun Zhu           2015   China      Hepatocellular carcinoma                     50            65           PFS         2.41 (1.61-13.70)   IHC                 \>25%
  Quan Zhou             2011   China      Osteosarcoma                                 65            55           PFS/OS      5.33 (0.57-49.56)   IHC                 \>51%

NR: not reporte; IRS: immunoreactivity score.

EMMPRIN overexpression and survival in cancers {#s2_2}
----------------------------------------------

We used Hazard ratio (HR) and the corresponding 95% confidence interval (CI) to estimate the prognostic value of EMMPPRIN overexpression in cancers. A fixed-effect model was used to conduct the analysis due to the Heterrogeneity test (I^2^=61%, P\<0.00001). The results indicated that EMMPRIN was significantly associated with OS in cancers (HR=2.46, 95% CI: 2.21-2.75, P\<0.0001) (Figure [2](#F2){ref-type="fig"}).

![Association between EMMPRIN overexpression and the outcome of cancer patients](oncotarget-08-82643-g002){#F2}

Besides, we also conducted subgroup analysis stratified by cancer type (Figure [3](#F3){ref-type="fig"}), ethnicity (Figure [4](#F4){ref-type="fig"}) and survival condition (Figure [5](#F5){ref-type="fig"}). Based on the cancer type group of studies, the investigation indicated that high EMMPRIN expression was associated with poor survival in bladder cancer (HR=2.21, 95% CI: 1.44-3.41, P\<0.0001), prostate cancer (HR=3.54, 95% CI: 2.10-5.97, P\<0.0001), gastrointestinal cancer (HR=2.96, 95% CI: 2.40-3.65, P\<0.0001), breast cancer (HR=2, 75, 95% CI: 1.37-5.50, P\<0.0001), cervical cancer (HR=2.63, 95% CI: 1.46-4.37, P\<0.0001), hepatocellular cancer (HR=2.26, 95% CI: 1.09-4.69, P\<0.0001), ovarian cancer (HR=1.37, 95% CI:1.02-1.83, P\<0.0001), glioma (HR=2.77, 95%CI: 1.44-5.31, P=0.002) and others (HR=2.72, 95% CI: 1.88-3.95, P\<0.0001). As for the population group of studies, both the Asian ethnicity (HR=2.63, 95% CI:2.32-2.99, P\<0.0001) and Caucasian ethnicity (HR=2.04, 95% CI:1.65-2.63, P\<0.0001), the EMMPRIN overexpression predicted a poor prognostic value in cancers. In addition, based on the survival condition, the subgroup results indicated that the high EMMPRIN was associated with OS (HR=2.83, 95% CI:2.47-3.24, P\<0.0001), PFS (HR=1.73, 95% CI:1.37-2.19, P\<0.0001) and OS/PFS (HR=2.22, 95% CI:1.63-3.03, P\<0.0001). All the results summarized were presented in Table [2](#T2){ref-type="table"}.

![Subgroup analysis results based on tumor type](oncotarget-08-82643-g003){#F3}

![Subgroup analysis results based on ethnicity](oncotarget-08-82643-g004){#F4}

![Subgroup analysis results based on survival condition](oncotarget-08-82643-g005){#F5}

###### Results of the overall and subgroup analyses for EMMPRIN overexpression and the outcome of cancer patients

  Categories                 No. of studies   Cases   Pooled HR   95% CI      P value
  -------------------------- ---------------- ------- ----------- ----------- ----------
  **Overall**                39               5739    2.46        2.21-2.75   \<0.0001
  **Cancer types**                                                            
   Bladder cancer            5                714     2.21        1.44-3.41   \<0.0001
   Prostate cancer           3                414     3.54        2.10-5.97   \<0.0001
   Gastrointestinal cancer   6                1459    2.96        2.40-3.65   \<0.0001
   Breast cancer             3                363     2.75        1.37-5.50   \<0.0001
   Cervical cancer           2                214     2.63        1.46-4.73   \<0.0001
   Hepatocellular cancer     2                104     2.26        1.09-4.69   \<0.0001
   Ovarian cancer            2                323     1.37        1.02-1.83   \<0.0001
   Others                    18               2148    2.60        2.18-3.10   \<0.0001
  **Population**                                                              
   Asian                     29               4382    2.63        2.32-2.99   \<0.0001
   Caucasian                 10               1357    2.04        1.65-2.63   \<0.0001
  **Survival conditions**                                                     
   OS                        23               3829    2.83        2.47-3.24   \<0.0001
   PFS                       7                992     1.73        1.37-2.19   \<0.0001
   OS/PFS                    9                918     2.22        1.63-3.03   \<0.0001

Moreover, because the clinicopathological characteristics and driven factors are different in different cancers, we conducted a subgroup analysis during the tumor-stage-analysis based on cancer types ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}). The results indicated that high expression of EMMPRIN predicted an advanced tumor stage, which means our conclusion was relatively consistent, except for cervical cancer (HR=1.35, 95%CI: 0.73-2.48, p=0.33). According to our analysis, the expression of EMMRIN was not significantly associated with tumor stage in cervical cancer.

Besides, the cut-off value was not consistent among the studies included, thus we conducted a subgroup analysis based on the criteria of positive expression definition. The high cut-off value was identified when the percentage of positive cells is more than 50% or the scores are more than 3. And the low cut-off value was indentified when the percentage of positive cells is less than 50% and the scores are less than 3. Besides, 5 studies \[[@R35], [@R45], [@R46], [@R52], [@R53]\] enrolled in our meta-analysis provided no information of the cu-off value. Thus, these 5 studies were not included in the present subgroup analysis based on the criteria of positive expression definition. The results indicated that the high or low cut-off value didn't affect our conclusion obviously (High: HR=2.76, 95%CI: 2.62-2.90, Low: HR=2.38, 95%CI: 2.33-2.44). Both the high cut-off value group and the low cut-off value group suggested the corresponding overexrepssion of EMMRIN predicted a poor prognosis outcome in cancers ([Supplementary Figure 2](#SD1){ref-type="supplementary-material"}).

EMMPRIN overexpression and clinicopathological features {#s2_3}
-------------------------------------------------------

All the results assessing the association between clinicopathological features and EMMPRIN expression were presented in Table [3](#T3){ref-type="table"}.

###### Results of clinicopathological factors related to EMMPRIN overexpression

  Subgroup                                 No. of studies   Cases   Pooled OR   95% CI      P value
  ---------------------------------------- ---------------- ------- ----------- ----------- ----------
  Tumor stage (T3+T4/T1+T2)                24               4769    1.87        1.64-2.12   \<0.0001
  Differentiation (poor/ well +moderate)   14               3476    1.09        1.60-2.23   \<0.0001
  Clinical stage (III+IV/I+II)             25               4734    1.96        1.69-2.27   \<0.0001
  Nodal metastasis (negative/ positive)    12               2010    2.37        1.93-2.90   \<0.0001

We conducted analysis evaluating the clinicopathological features and EMMPRIN expression from the following aspects: tumor stage (Figure [6](#F6){ref-type="fig"}), differentiation (Figure [7](#F7){ref-type="fig"}), clinical stage (Figure [8](#F8){ref-type="fig"}) and nodal metastasis (Figure [9](#F9){ref-type="fig"}).

![Association between EMMPRIN overexpression and tumor stage](oncotarget-08-82643-g006){#F6}

![Association between EMMPRIN overexpression and tumor differentiation](oncotarget-08-82643-g007){#F7}

![Association between EMMPRIN overexpression and clinical stage](oncotarget-08-82643-g008){#F8}

![Association between EMMPRIN overexpression and nodal metastasis](oncotarget-08-82643-g009){#F9}

Among the included studies, 24 studies reported risk between high EMMPRIN expression and tumor stage. The results obviously indicated that the positive rate of EMMPRIN expression was significantly higher in cancers with tumor stage T3+T4 than with stageT1+T2 (OR=1.87, 95% CI:1.64-2.12, P\<0.0001). Besides, the EMMPRIN overexpression was significantly associated with tumor differentiation (poor/ well+ moderate) (OR=1.09, 95% CI:1.60-2.23, P\<0.0001). Stratified based on the clinical stage, the results showed a significant association between EMMPRIN expression and the risk of clinical stage III+IV than stage I +II (OR=1.96, 95% CI:1.69-2.27, P\<0.0001). 12 studies compared the EMMPRIN expression negative nodal metastasis and positive nodal metastasis. The results showed that a higher EMMPRIN expression indicated a positive nodal metastasis (OR=2.37, 95% CI:1.93-2.90, P\<0.0001).

Quality assessment and sensitivity analysis {#s2_4}
-------------------------------------------

The quality of each study included in our meta-analysis was assessed using The Newcastle-Ottawa Scale (NOS). A star system was used to calculate the score of each study and a study award with 5 scores or more was considered as high quality article. The scores of the 39 studies include in our research ranged from 7 to 9.

By omitting one individual study a time, sensitivity analysis between EMMPRIN overexpression and survival of cancer was conducted to investigate the potential sources of heterogeneity (Figure [10](#F10){ref-type="fig"}). The results indicated that overall risk estimate did not change, indicating a stable result of our meta-analysis.

![Sensitivity test among studies included](oncotarget-08-82643-g010){#F10}

Publication bias {#s2_5}
----------------

According to the funnel plot (Figure [11](#F11){ref-type="fig"}), no evidence of obvious asymmetry existed. Furthermore, Begg's funnel plot and Egger;s regression were also conducted to estimate the publication bias. The results (Table [4](#T4){ref-type="table"}) showed no significant publication bias for pooled HR estimation. Similarly, there is no publication bias existed in the OR estimation and the subgroup of the analysis.

![Funnel plot analysis investigating the publication bias between EMMPRIN overexpreession and cancer prognosis](oncotarget-08-82643-g011){#F11}

###### Results of Egger's and Begg's tests

  Comparison   N    Egger\'s test   Begg\'s test                         
  ------------ ---- --------------- -------------- -------------- ------ -------
  Overall      48   1.4             0.167          (-0.30-1.69)   0.02   0.986
  OS           28   -0.15           0.879          (-1.89-1.63)   0.18   0.859
  PFS          11   1.31            0.224          (-0.73-2.71)   0.62   0.533
  OS/PFS       9    4.67            0.002          (0.77-2.34)    1.15   0.251
  Caucasian    10   1.71            0.127          (-0.47-3.12)   0.89   0.371
  Asian        38   0.45            0.653          (-0.97-1.53)   0.62   0.538

DISCUSSION {#s3}
==========

Most cancer deaths are due to metastasis with proliferation and angiogenesis \[[@R54]\]. Matrix metalloproteinases (MMPs), found in extracellular milieu of various tissues, are reported to be associated with poor survival of cancer patients \[[@R55]\]. Because of the specific structure, MMPs are responsible for the cancer metastasis, invasion, angiogenesis and tumorigenesis \[[@R56], [@R57]\]. And the MMPs are obviously up-regulated by the stimulated EMMPRIN, which makes EMMPRIN get involved with tumor metastasis \[[@R58]\]. It's reported that EMMPRIN and MMP-9 can be found in normal keratinocytes \[[@R59]\] and tumor cells \[[@R60]\] and the expression of EMMPRIN is much higher in tumor tissues than the adjunct normal tissues \[[@R61]\]. Besides, EMMPRIN can interact with a verity of proteins, such as VEGF \[[@R62]\], lewis y antigen \[[@R63]\], caveolin-1 \[[@R64]\], cyclooxygenase-2 \[[@R65]\] and fascin \[[@R66]\], executing its effect on tumorigenesis by regulating tumor cell invasion, metastasis and adhesion.. Emerging evidence indicate that EMMPRIN is associated with prognosis of various cancers, however, the exact effects remains vaguely.

In the present study, the data from 39 studies with 5739 cases were analyzed to assess the association between EMMPRIN overexpression and its prognostic value in cancer. According to our analysis, EMMPRIN was significantly associated with poor outcome of cancer patients (HR=2.46, 95% CI: 2.21-2.75, P\<0.0001). It's been reported that in hepatocellular carcinomas, higher EMMPRIN expression correlates significantly with poor survival of patients. In breast cancer, the OS of patients with higher EMMPRIN expression was much shorter than those with lower EMMPRIN expression. The same situation also exists in other cancers. Our finding is consistent with the previous studies investigating the roles of EMMPRIN overexpression. Besides, our results revealed that higher expression of EMMPRIN was also an independent risk factor for the survival of cancer patients in Asian and Caucasian based on the subgroup stratified by ethnicity. The similar results are summarized when stratified by survival conditions.

To further investigate the prognostic value of EMMPRIN, the relationship between EMMPRIN expression and the clinicopathological factors was also analyzed in our meta-analysis. Our results suggested that higher EMMPRIN expression was obviously associated with worse clinicopathological features, including tumor stage (T3+T4/T1+T2), except for cervical cancer (HR=1.35, 95%CI:0.73-2.48, p=0.33), poor/ well+ moderate differentiation rate, clinical stage (III+IV / I +II) and nodal metastasis (negative/positive). This may also verify the strong association between EMMPRIN expression and the survival of tumor patients. This might be the first study to evaluate the clinicopathological significance of EMMPRIN in cancers. However the other clinicopathological factors, such as age, tumor location and sex, were not included in our analysis. Considering the complicacy of clinicopathological features, more studies on large populations are encouraged.

Because of the inconsistent method to test the EMMPRIN expression and positive criteria, we also analyzed the corresponding heterogeneity. Among all the 39 studies, 4 studies used TMA to detect the expression of EMMPRIN; the rest 35 studies used IHC to detect the expression of EMMPRIN, as indicated in our revised Table [1](#T1){ref-type="table"}. Among these, 5 studies didn't mention the cut-off value of positive expression of EMMPRIN. Both the percentage of positive cells and the intensity of staining scores were used according to different studies. However, the results indicated that our conclusion was relatively consistent. No obvious discrepancy was found during the analysis. Although the pathogeneses of different cancer types are divergent, our results could prove the prognostic value of EMMPRIN in cancers for the reasons below. First, high expression of EMMPRIN predicted worse overall survival in each sub grouped cancer. Second, elevated EMMPRIN expression was significantly associated with poor survival of cancer patients in a pooled analysis in all included cancers. It means that EMPPRIN might be a universally applicable biomarker in cancers.

The mechanism lied behind this correlation still remain unknown. MMPs stimulated by EMMPRIN in human cancers may account for one of these mechanisms. By activating signal transduction cascades through degrading extracellular matrix proteins, MMPs can enhance tumor metastasis and invasion \[[@R37]\]. It's also been demonstrated that tumor progression could be inhibited by silencing EMMPRIN by RNA interference approach \[[@R67], [@R68]\]. In order to select a therapeutic strategy and to allocate medical resources with reasonableness, an accurate method to predict the prognosis of cancer patients is required \[[@R69]\]. Our meta-analysis concluded that EMMPRIN could be a prognostic marker in solid tumors.

However, some limitations still exist in result of the current meta-analysis. First, for subgroup analysis stratified by cancer type, some types have insufficient studies to summarize the main effect, such as gallbladder carcinoma and penis carcinoma. Second, several studies included used Engage Digitizer 4.1 to estimate the data because only Kaplan-Meier curve was provided, thereby leading to unavoidable calculation errors. Third, some clinicopathological factors, such as age, tumor location and sex, were not included in our analysis due to the insufficient data. Fourth, the cut-off values were inconsistent in the studies included, and this could be one source of heterogeneity. Therefore, more well-designed studies are needed to validate the findings of the current study.

In conclusion, EMMPRIN overexpression predicts a poor prognosis outcome of cancer patients and is significantly relevant to clinicopathological features. Therefore, EMMPRIN might be a reasonable prognostic bio-maker and therapeutic target of cancer.

MATERIALS AND METHODS {#s4}
=====================

There is no review protocol exists.

Literature search {#s4_1}
-----------------

We comprehensively searched for published literature by consulting the electronic database PubMed, Cochrane Library databases and Web of Science before October 10, 2016, without language and publication restrictions. Studies were selected using the following terms: "Extracellular matrix metalloproteinase inducer" or "EMMPRIN" or "CD147" or "HAb18G" and "basigin" in combination with "cancer," "tumor," "carcinoma" and "neoplasm". The references of retrieved articles were also reviewed for any potential eligible data and authors were contacted for specific information if necessary. Oncomine (User ID: <1610636@tongji.edu.cn>) and TCGA (analyzed by cBioPortal) were searched to make our research complete. The literature search was performed independently by H. Fan and W. Yi with double check and consensus to resolve all the disagreements.

Study selection {#s4_2}
---------------

The studies were included if they met the following criteria: 1) the article enrolled should be case-control and cohort study; 2) expression of EPPRIN needs to be identified as positive with specific methods in cancer patients; 3) the relationship between EPPRIN expression and the time-to-event outcome, which was precisely defined, was reported; 4) sufficient data was provided to calculate the odds ratio (OR) and the hazard ratio (HR) with the corresponding 95% confidence intervals (CI) (ether directly obtained or indirectly calculated from Kaplan-Meier survival curves). Studies were ineligible if they were case reports, reviews, letters, duplicate studies, and articles without sufficient data. If more than one article focused on the same population, we preferred the latest one.

Data extraction {#s4_3}
---------------

Information was carefully extracted from all the eligible studies by two investigators (H. Fan and C. Wang) independently, including: the first author's name, publication year, the ethnicity, cancer type, sample size, testing method, survival condition, duration of follow-up, EPPRIN expression data and the HRs and ORs with the corresponding 95% CI. Software Engauge Digitizer 4.1 was used to extract data if the study provided a Kaplan-Meier curve only.

Quality assessment {#s4_4}
------------------

We used Newcastle-Ottawa Quality Assessment Scale (NOS) to evaluate the quality of every study enrolled. Each item could be awarded with one point when meeting the requirement (total score ranged from 0 to 9). Studies got a score of 6 or more were considered to be of high quality.

Statistical analysis {#s4_5}
--------------------

Review Manager 5.3 was used to perform all statistical analyses. Hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) were used to evaluate the significance of the association between EPPRIN expression and the outcome of patients. The odds ratios (ORs) and corresponding 95%CI were used to analyze the correlation between EPPRIN overexpression and clinicopathological parameters, such as tumor stage, nodal metastasis and clinical grade. *Q*-test and *I*^*2*^ index were used to assess the heterogeneity between studies. A random-effects model was conducted when the heterogeneity was considered statistically significant (*P*\<0.01). Otherwise, a fixed-effects model was conducted. Begg's and Egger's asymmetry tests were used to assess the potential publication bias. By omitting a study one time, sensitivity analysis was conducted to assess the stability of our results. Begg's and Egger's asymmetry tests and sensitivity analysis were performed by STATA software version 12.0 (STATA Corporation, College Station, TX, USA).

SUPPLEMENTARY MATERIALS FIGURES {#s5}
===============================
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